Retatrutide Weight Loss and Gray Market Risks

In today's episode we're diving deep into retatrutide, the groundbreaking triple hormone receptor agonist making waves in obesity treatment.

We explore how scientific clinical research highlights its remarkable weight loss results for patients with obesity and diabetes, showing how it effectively regulates metabolism and blood glucose levels.

We also detail its safety profile and common side effects identified in clinical trials. Furthermore, we uncover the critical real-world risks associated with gray-market sourcing, unregulated online peptides, and self-administration.

Tune in to discover the clinical promise, potential side effects, and important health warnings surrounding this novel metabolic therapy for modern weight management.

=== REFERENCES ===

• https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
• https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
• https://doi.org/10.3389/fmed.2026.1763185
• https://github.com/sehgal-neil/retatrutide_side_effect_analysis

---

If you enjoy FoodNourish Deep Dives and want to help support our independent research, consider becoming a supporter for just 2€ per month! 👇


Become a supporter of this podcast: https://www.spreaker.com/podcast/foodnourish-deep-dives--6602003/support.

🤗 Support the show: Become a supporter for just 2€ per month to remove advertisements and help us continue bringing interesting topics while confronting mainstream narratives on health.

Support FoodNourish Deep Dives

This episode includes AI-generated content.